Clinical Trials Sponsored by Thai Otsuka Pharmaceutical Co.,Ltd.

Total 3851 results

Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

A Clinical Study of TQH2929 in Healthy Adult Subjects

Psoriasis

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer

Breast Cancer

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps.

Sinusitis

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors

Hematological Tumors

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Terminated

Clinical Trial of TQB2858 Injection in the Treatment of Advanced High-grade Sarcoma

Advanced High-grade Sarcoma

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors

Osteosarcoma | Other Solid Tumors

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers

Advanced Cancer

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

A Clinical Trial of AP026 (TQA2226) for Injection in Adult Subjects.

Diabetes Mellitus, Type 2

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Mantle Cell Lymphoma

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Not yet recruiting

Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers

Advanced Cancer

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Not yet recruiting

Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors

Advanced Tumors

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors

Advanced Malignant Tumor

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Terminated

A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma

Pancreatic Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Not yet recruiting

A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)

Generalized Pustular Psoriasis

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Not yet recruiting

A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer

Biliary Tract Cancer

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

A Clinical Trial of TQH3906 Capsules in Healthy Volunteers

Psoriasis

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

Clinical Trial Evaluating the Safety of the TQB2103 for Injection

Advanced Malignant Neoplasm

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects

Atopic Dermatitis

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers

Advanced Cancers

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers

Advanced Cancer

China
Peking University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Beijing Biostar Pharmaceuticals...

Recruiting

Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer

Esophageal Cancer

China
Taiwan Otsuka Pharm. Co., Ltd

Completed

A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients

Glaucoma

Taiwan
Taiwan Otsuka Pharm. Co., Ltd

Completed

Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia

Schizophrenia | Schizoaffective Disorder

Taiwan
Korea Otsuka Pharmaceutical Co., Ltd.
Seoul National University Boramae Hospital; Korea Otsuka International Asia...

Completed

Cilostazol in Acute Ischemic Stroke Treatment (CAIST)

Cerebral Infarction

Korea, Republic of
Taiwan Otsuka Pharm. Co., Ltd

Completed

Aripiprazole for the Augmentation of Antidepressant Therapy

Major Depressive Disorder

Taiwan
Taiwan Otsuka Pharm. Co., Ltd

Completed

A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler® and Ventolin® MDI in Stable Asthma Patients

Asthma

Taiwan
Taiwan Otsuka Pharm. Co., Ltd

Completed

Health Evaluation of Abilify Long-term Therapy (HEALTH)

Schizophrenia | Schizoaffective Disorder

Taiwan
Osaka University
Rohto Pharmaceutical Co., Ltd.

Recruiting

ADR-002K for Patients With Ischemic Cardiomyopathy Who Undergo Coronary Artery Bypass Surgery

D017202

Japan
Seoul National University Hospital
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease (IMPACTonIMT)

Hyperlipidemias

Korea, Republic of
Gyeongsang National University Hospital
Korea Otsuka Pharmaceutical Co., Ltd.

Unknown

Cilostazol and Endothelial Progenitor Cell (EPISODE)

Myocardial Infarction, Acute
UCB BIOSCIENCES GmbH
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

Advanced Idiopathic Parkinson's Disease

Korea, Republic of, United States, Malaysia, Singapore, Taiwan
Seoul National University Hospital
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders

Bipolar Disorders | Metabolic Complication

Korea, Republic of
Chonnam National University Hospital
Korea Otsuka Pharmaceutical Co., Ltd.

Unknown

Busulfan and Melphalan Conditioning in Multiple Myeloma

Multiple Myeloma

Korea, Republic of
Seoul National University Hospital
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia

Schizophrenia

Korea, Republic of
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma

T-lymphoblastic Lymphoma | T-lymphoblastic Leukemia

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors

Advanced Cancers

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)

Myelofibrosis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy

Hematologic Malignancy

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets

Myelofibrosis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.

Biliary Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).

Advanced Hepatocellular Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers

Advanced Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Hepatocellular Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis

Rheumatoid Arthritis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Squamous Cell Carcinoma of the Head and Neck | Metastatic Squamous Cell Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Study of Polyglycan Superparamagnetic Ferric Oxide Injection on Cardiovascular Magnetic Resonance Imaging

Chronic Kidney Diseases | Magnetic Resonance Imaging

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects

Multiple Myeloma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China

Clinical Trials Sponsored by Thai Otsuka Pharmaceutical Co.,Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations